NUS Scientists Develop Dry Eye Cure with Plant Power: A Revolutionary Approach to Eye Health
The world of medicine is constantly evolving, and the latest breakthrough from the National University of Singapore (NUS) is nothing short of remarkable. Imagine a treatment for dry eye disease that harnesses the power of plants and light to heal the eyes. This is not science fiction but a real-life innovation that could change the way we approach eye health.
Dry eye disease, a common condition affecting over 1.5 billion people worldwide, has long been a source of discomfort and pain. It causes corneal scarring, chronic pain, blurred vision, and sensitivity to light, impacting daily life and productivity. Current treatments, such as cyclosporine A (Restasis®) and lifitegrast (Xiidra®), target inflammation but come with high costs and adverse side effects, limiting their long-term use.
The NUS team, led by Associate Professor David Leong Tai Wei, has developed a groundbreaking approach by transplanting functional plant-derived photosynthetic machinery into corneal cells. This innovation, known as LEAF (Light-reaction Enriched thylAkoid NADPH-Foundry), is a nanosized, structurally preserved version of the thylakoid grana, the light-reactions machinery of photosynthesis in plant cells. By stripping away the part of the chloroplasts that consumes NADPH and keeping the thylakoids intact, LEAF acts as a dedicated NADPH factory, producing about 20% more NADPH compared to unpackaged thylakoids.
The core innovation lies in the ability to produce photosynthetic NADPH upon exposure to ambient light sources. This NADPH tackles dry eye disease via two pathways: inside and outside the cell. In laboratory tests, LEAF restored NADPH levels within 30 minutes of light exposure, suppressed ROS, and pivoted immune cells in the cornea from a pro-inflammatory to an anti-inflammatory state. When tested directly in tear samples from patients with dry eye disease, LEAF increased NADPH levels roughly 20-fold and reduced hydrogen peroxide, a key cell-damaging oxidant, by more than 95%.
The team's work is not just a scientific achievement but also a fascinating exploration of the intersection between plants and animals. Evolutionarily, plants and animals have taken divergent paths, with animals unable to photosynthesise, except for the sacoglossan sea slug, which can live off the nutrients made through photosynthesis. This raises the intriguing question: could mammals also acquire some limited form of photosynthesis?
The NUS researchers chose the eye as it is one of the few organs in the human body that absorbs visible light, just like plant leaves. By engineering LEAF, they have demonstrated that plant photosynthetic machinery can be transplanted into mammalian tissue to generate biologically useful molecules, powered entirely by the same light that enables our vision. This is an exciting finding that opens up new possibilities for eye health and beyond.
The potential of LEAF extends beyond dry eye disease. As oxidative stress underpins a wide range of inflammatory conditions, the team sees potential for LEAF-based approaches wherever the body's antioxidant defences are overwhelmed, particularly in tissues naturally accessible to visible light such as the retina, skin, and underlying skeletal muscles. They are also developing new strategies that can produce therapeutically useful photosynthesised molecules in internal organs without the need for visible light penetration.
In conclusion, the NUS team's work is a remarkable example of how scientific innovation can lead to groundbreaking solutions. By harnessing the power of plants and light, they have developed a simple, effective, and non-invasive treatment for dry eye disease. This is a significant step forward in eye health, and the potential for further applications is vast. As the team continues to explore the possibilities, we can look forward to a future where human cells have some limited but beneficial form of photosynthetic ability, not only in the eye but elsewhere too.
